Vanguard Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-2,767,268
Closed -$12.8M 4197
2019
Q1
$12.8M Buy
2,767,268
+655,261
+31% +$3.1M ﹤0.01% 2696
2018
Q4
$7.39M Sell
2,112,007
-549,317
-21% -$3.82M ﹤0.01% 2914
2018
Q3
$26.8M Buy
2,661,324
+119,776
+5% +$955K ﹤0.01% 2445
2018
Q2
$18.4M Buy
2,541,548
+151,546
+6% +$1.06M ﹤0.01% 2600
2018
Q1
$14.4M Sell
2,390,002
-147,084
-6% -$1.21M ﹤0.01% 2631
2017
Q4
$24.4M Buy
2,537,086
+244,979
+11% +$1.6M ﹤0.01% 2413
2017
Q3
$20.4M Sell
2,292,107
-41,147
-2% -$425K ﹤0.01% 2484
2017
Q2
$29.5M Sell
2,333,254
-17,853
-0.8% -$211K ﹤0.01% 2282
2017
Q1
$24.7M Sell
2,351,107
-29,785
-1% -$317K ﹤0.01% 2360
2016
Q4
$21.9M Sell
2,380,892
-1,812
-0.1% -$20.5K ﹤0.01% 2385
2016
Q3
$28.1M Sell
2,382,704
-2,077
-0.1% -$31.6K ﹤0.01% 2208
2016
Q2
$30.9M Sell
2,384,781
-107,214
-4% -$1.56M ﹤0.01% 2131
2016
Q1
$39.8M Buy
2,491,995
+216,373
+10% +$4.11M ﹤0.01% 1969
2015
Q4
$65.2M Buy
2,275,622
+414,581
+22% +$11.5M ﹤0.01% 1757
2015
Q3
$53M Buy
1,861,041
+61,149
+3% +$2.25M ﹤0.01% 1837
2015
Q2
$64.7M Buy
1,799,892
+76,662
+4% +$2.39M ﹤0.01% 1796
2015
Q1
$50.1M Buy
1,723,230
+469,136
+37% +$12.4M ﹤0.01% 1911
2014
Q4
$26.4M Sell
1,254,094
-38,810
-3% -$767K ﹤0.01% 2139
2014
Q3
$25.1M Buy
1,292,904
+306,126
+31% +$4.81M ﹤0.01% 2109
2014
Q2
$15.4M Buy
986,778
+27,904
+3% +$451K ﹤0.01% 2315
2014
Q1
$19.9M Buy
958,874
+574,430
+149% +$11.4M ﹤0.01% 2181
2013
Q4
$4.96M Buy
384,444
+113,586
+42% +$1.58M ﹤0.01% 2804
2013
Q3
$3.16M Buy
270,858
+20,331
+8% +$167K ﹤0.01% 2950
2013
Q2
$1.16M Buy
+250,527
New +$918K ﹤0.01% 3266

Other funds holding INSY

Vanguard Group's INSY Position: Q2 2019 in Review

Vanguard Group sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 2,767,268 shares — an estimated $12.8M sold.

Vanguard Group first reported a position in INSY in Q2 2013 and held it in 24 quarters. The position peaked at $65.2M in Q4 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Vanguard Group reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Vanguard Group sold 2,767,268 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $12.8M.
  • Vanguard Group first reported a position in Insys Therapeutics, Inc. in Q2 2013 and held it in 24 quarters.
  • Vanguard Group's Insys Therapeutics, Inc. position peaked at $65.2M in Q4 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Vanguard Group's 13F filing for Q2 2019, filed 14 Aug 2019.